Maia Biotechnology
Maia Biotechnology is a United States-based biotechnology company running 2 late-stage cancer trials in non-small-cell lung cancer.
Overview
Maia Biotechnology, based in Chicago, the United States, is a biotechnology company. Maia Biotechnology is a clinical-stage biopharmaceutical company that develops telomere-targeting immunotherapies for cancer. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3) in non-small-cell lung cancer. The largest, NCT06908304 (A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC), plans to enrol 300 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyAvistone Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanySTCube
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCivaTech Oncology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyKrystal Biotech
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanymAbxience Research S.L.
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCelltrion
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCatalYm
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyGenprex
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.